- Home
- NYC vs CASI Comparison
NYC vs CASI Comparison
Compare NYC & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- CASI
- Stock Information
- Founded
- NYC 2013
- CASI 1991
- Country
- NYC United States
- CASI China
- Employees
- NYC N/A
- CASI N/A
- Industry
- NYC Real Estate
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- CASI Health Care
- Exchange
- NYC Nasdaq
- CASI Nasdaq
- Market Cap
- NYC 30.7M
- CASI 29.7M
- IPO Year
- NYC N/A
- CASI 1996
- Fundamental
- Price
- NYC $10.55
- CASI $1.91
- Analyst Decision
- NYC
- CASI Strong Buy
- Analyst Count
- NYC 0
- CASI 1
- Target Price
- NYC N/A
- CASI $4.00
- AVG Volume (30 Days)
- NYC 3.1K
- CASI 7.5K
- Earning Date
- NYC 05-09-2025
- CASI 05-27-2025
- Dividend Yield
- NYC N/A
- CASI N/A
- EPS Growth
- NYC N/A
- CASI N/A
- EPS
- NYC N/A
- CASI N/A
- Revenue
- NYC $58,397,000.00
- CASI $28,537,000.00
- Revenue This Year
- NYC $8.40
- CASI N/A
- Revenue Next Year
- NYC $1.62
- CASI N/A
- P/E Ratio
- NYC N/A
- CASI N/A
- Revenue Growth
- NYC N/A
- CASI N/A
- 52 Week Low
- NYC $7.55
- CASI $1.64
- 52 Week High
- NYC $13.59
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- NYC 40.02
- CASI 46.41
- Support Level
- NYC $10.68
- CASI $1.81
- Resistance Level
- NYC $11.77
- CASI $1.95
- Average True Range (ATR)
- NYC 0.64
- CASI 0.10
- MACD
- NYC -0.09
- CASI 0.00
- Stochastic Oscillator
- NYC 0.00
- CASI 61.36
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.